

## REMARKS

In accordance with the present amendment, the specification has been amended to include a claim of priority to U.S. Provisional Patent Applications Nos. 60/431,549 and 60/480,138. While drafting the response to the October 11, 2006 Official Action in this application, it was noted that although a proper claim to the benefit of the aforementioned provisional patent applications is made in the Declaration of Inventorship (Form PCT/RO1101) in this case, and reference is made to the provisional patent applications in the Sequence Listing, the specification omitted a claim to the benefit of the provisional patent applications in the manner specified in 37 CFR §1.78(a)(5)(iii). The present specification amendment is presented to supply such omission.

A petition and surcharge for unintentionally delayed priority claim should not be required in this case, as the exception provided in §201.11(a) of the Manual of Patent Examining Procedure is believed to apply, the information concerning the benefit claim having been included on the filing receipt for this application (copy enclosed). It is also noted that the information concerning the benefit claim appears in U.S. Patent Application Publication No. 2006/0122110 A1. A copy of the cover page of U.S. Patent Application Publication No. 2006/0122110 A1 is also enclosed.

No new matter has been introduced into this application by reason of the amendment presented herewith, entry of which is respectfully requested.

Respectfully submitted,

DANN DORFMAN HERRELL and SKILLMAN, P.C.  
Attorneys for Applicant

By Patrick J. Hagan  
Patrick J. Hagan  
Registration No. 27,643

Customer Number 000110  
(215) 563-4100 (telephone)  
(215) 563-4044 (facsimile)  
[phagan@ddhs.com](mailto:phagan@ddhs.com) (email)



US 20060122110A1

(19) **United States**(12) **Patent Application Publication**  
**Xiao**(10) **Pub. No.: US 2006/0122110 A1**(43) **Pub. Date: Jun. 8, 2006**(54) **NOGO, CASPR, F3 NB-3 USEFUL IN THE  
TREATMENT OF INJURY AND DISEASE TO  
THE CENTRAL NERVOUS SYSTEM****Publication Classification**(76) **Inventor: Zhi-Cheng Xiao, Singapore (SG)**(51) **Int. Cl.****A61K 38/17 (2006.01)****Correspondence Address:****DANN, DORFMAN, HERRELL & SKILLMAN  
1601 MARKET STREET  
SUITE 2400  
PHILADELPHIA, PA 19103-2307 (US)**(52) **U.S. Cl. 514/12**(57) **ABSTRACT**(21) **Appl. No.: 10/537,757**(22) **PCT Filed: Dec. 5, 2003**(86) **PCT No.: PCT/GB03/05329****Related U.S. Application Data**(60) **Provisional application No. 60/431,549, filed on Dec.  
6, 2002. Provisional application No. 60/480,138, filed  
on Jun. 20, 2003.**

The application provides materials and methods for promoting myelination of neuronal axons in the CNS. These derive from the findings firstly that the molecules Nogo and Caspr interact with one another during establishment and maintenance of the axoglial junction, and secondly that the molecules F3 and NB-3 are capable of promoting oligodendrocyte maturation via interaction with Notch. The materials and methods provided may be used in the treatment of CNS damage, in particular the treatment of spinal cord injury, multiple sclerosis, epilepsy and stroke.

**BEST AVAILABLE COPY**




**UNITED STATES PATENT AND TRADEMARK OFFICE**

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/537,757	06/06/2005	1614	1500	0380-P03638USO	43	20	2

**CONFIRMATION NO. 5465**

**FILING RECEIPT**



\*OC000000018006628\*

110  
DANN, DORFMAN, HERRELL & SKILLMAN  
1601 MARKET STREET  
SUITE 2400  
PHILADELPHIA, PA 19103-2307

Date Mailed: 02/22/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**  
Zhi-Cheng Xiao, Singapore, SINGAPORE;

**Power of Attorney:** The patent practitioners associated with Customer Number 110.

**Domestic Priority data as claimed by applicant**

This application is a 371 of PCT/GB03/05329 12/05/2003  
which claims benefit of 60/431,549 12/06/2002  
and claims benefit of 60/480,138 06/20/2003

**Foreign Applications**

**Projected Publication Date:** To Be Determined - pending completion of Security Review

**Non-Publication Request:** No

**Early Publication Request:** No

**Title**

Nogo, caspr, f3 nb-3 useful in the treatment of injury and disease to the central nervous system

**BEST AVAILABLE COPY****Preliminary Class**

514

**PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES**

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject

matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).